Table 3.
Genetically engineered mouse models of Loxl2 and Loxl3 related to cancer.
| Gene | Genetic Model | Cancer Model | Phenotype | Ref. |
|---|---|---|---|---|
| Loxl2 constitutive |
Loxl2 KO | DMBA/TPA mouse skin carcinogenesis |
Decreased tumour burden and malignant progression | [122] |
| Loxl2 KI | DMBA/TPA mouse skin carcinogenesis |
Decreased latency, increased tumour burden, and malignant progression |
[122] | |
| Loxl2 KO | Spontaneous uterine cancer | Uterine hyperplasia and uterine carcinomas | [17] | |
| L2ΔE3 KI | Oesophageal cancer | Metabolic reprograming | [16] | |
| Loxl2 conditional |
Loxl2 KO (mammary glands) |
MMTV-PyMT-breast cancer | Decreased lung metastasis | [142] |
| Loxl2 KI (mammary glands) |
MMTV-PyMT-breast cancer | Increased lung metastasis | [142] | |
| Loxl2 KO (pancreatic tumours) |
KPC (Kras/Tp53/Pdx1-Cre)-L2-KO/ KC (Kras/Pdx1-Cre)-L2-KO |
Decreased metastasis, increased overall survival. Alteration in collagen crosslinking |
[39] | |
| Loxl2 KI (pancreatic tumours) |
KPC (Kras/Tp53/Pdx1-Cre)-L2-KI/ KC (Kras/Pdx1-Cre)-L2-KI |
Increased metastasis and tumour growth, decreased overall survival. Induction of EMT and stemness. |
[39] | |
| Loxl3 conditional/ inducible |
Loxl3 (melanoma) |
Tyr-CreER/Braf/Pten/L3-KO | Decreased tumour burden and reduced lymphatic dissemination |
[143] |